# US 5,789,388 A · Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,789,388 A
- Document ID: US5789388A
- Status: Granted
- Kind: A
- Application number: 08/359,980
- Filed: 1994-12-20
- Granted: 1998-08-04
- Earliest claimed: 1993-12-21
- Assignees: Akzo Nobel N.V.
- Inventors: Nicolaas Visser; Petrus Alphonsus Maria van Woensel; Thomas Christoph Mettenleiter
- Web page: https://patentgrep.com/patent/US5789388A

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2710/16722: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16743: viral genome or elements thereof as genetic vector
- C12N 2710/16761: Methods of inactivation or attenuation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a vaccine against a virus associated with antibody-dependent-enhancement of viral infectivity. Such a vaccine comprises a herpesvirus vector which is able to spread from cell-to-cell and which does produce non-infectious progeny virions having a gene encoding an antigen of said virus inserted into the herpesvirus genome.

## Claims

### Claim 1

A vector comprising a live pseudorabies virus, Which is able to spread from cell-to-cell in a non-complementing cell culture and which produces non-infectious progeny virions, wherein the vector harbors a gene encoding an antigen of a virus associated with antibody-dependent enhancement (ADE) of viral infectivity, wherein said virus is selected from the group consisting of FIPV, PRRSV, EAV, African Swine Fever virus, FIV and HIV.

### Claim 2 (depends on 1)

The vector according to claim 1, wherein the pseudorabies virus is genotypic gp50.sup.- and phenotypic gp50.sup.+.

### Claim 3 (depends on 1)

A non-complementing cell culture comprising a live pseudorabies virus vector according to claim 1 in a cell-associated form.

### Claim 4 (depends on 1)

A vaccine for the protection of a host against a virus associated with ADE of viral infectivity and for intra-nasal administration, which vaccine comprises a live pseudorabies virus vector according to claim 1, and a pharmaceutically acceptable carrier or diluent.

### Claim 5 (depends on 4)

A method for immunizing a host against a virus associated with ADE of viral infectivity, comprising administering an effective amount of the vaccine according to claim 4.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said vaccine is administered intranasally.